Disclosed is a method for preparing a cell growth scaffold having a structural memory feature, comprising a step of preparing a micro-fibrous or flocculent acellular tissue matrix material; a step of preparing an acidification-treated hydrogel-like acellular tissue matrix particles; proportionally mixing the micro-fibrous or flocculent acellular tissue matrix material with the acidification-treated hydrogel-like acellular tissue matrix particles, followed by injection-molding, freezing treatment, radiation treatment, and ultimately preparing a porous cell growth scaffold that can be stored at room temperature. The prepared cell growth scaffold is a porous cell growth scaffold that has no chemical crosslinking, and has a biological activity, a stable three-dimensional structure and a structural memory feature. The cell growth scaffold has an excellent biocompatibility and complete biodegradability, and supports the growth of cells and the growth of tissues and organs in vitro and in vivo, thereby being suitable for repair of human soft tissue traumas and defects.

Methods for treating tissue matrices and tissue matrices produced according to the methods are provided. The methods can include treating select portions of a tissue matrix with a fluid containing at least one agent to produce a tissue matrix with variable mechanical and/or biological properties.

The present disclosure relates to methods and compositions comprising dissociated buccal mucosa tissue that are useful for treating a wound. Kits for preparing the liquid suspension of dissociated buccal mucosa tissue and treating the wound are also disclosed.

ECM based compositions including acellular ECM and antibiotics, and methods for employing same to treat damaged cardiovascular tissue and, thereby, disorders.

Described are packaged, sterile medical graft products containing controlled levels of a growth factor such as Fibroblast Growth Factor-2 (FGF-2). Also described are methods of manufacturing medical graft products wherein processing, including sterilization, is controlled and monitored to provide medical graft products having modulated, known levels of a extracellular matrix factor, such as a growth factor, e.g. FGF-2. Preferred graft materials are extracellular matrix materials isolated from human or animal donors, particularly submucosa-containing extracellular matrix materials. Further described are ECM compositions that are or are useful for preparing gels, and related methods for preparation and use.

A method for producing a decellularized tissue includes steps of lysing a cell of a biological tissue using a liquid containing a liquefied gas, and degrading a nucleic acid component contained in the lysed cell of the biological tissue using a nucleolytic enzyme.

Described are methods for producing multi-layered tubular tissue structures, tissue structures produced by the methods, and their use.

This invention relates to the design and function of a compressible valve replacement prosthesis, collared or uncollared, which can be deployed into a beating heart without extracorporeal circulation using a transcatheter delivery system. The design as discussed focuses on the deployment of a device via a minimally invasive fashion and by way of example considers a minimally invasive surgical procedure preferably utilizing the intercostal or subxyphoid space for valve introduction. In order to accomplish this, the valve is formed in such a manner that it can be compressed to fit within a delivery system and secondarily ejected from the delivery system into the annulus of a target valve such as a mitral valve or tricuspid valve.

Compositions of the invention for regenerating defective or absent myocardium comprise an emulsified or injectable extracellular matrix composition. The composition may also include an extracellular matrix scaffold component of any formulation, and further include added cells, proteins, or other components to optimize the regenerative process and restore cardiac function.

This invention relates to the design and function of a compressible valve replacement prosthesis, collared or uncollared, which can be deployed into a beating heart without extracorporeal circulation using a transcatheter delivery system. The design as discussed focuses on the deployment of a device via a minimally invasive fashion and by way of example considers a minimally invasive surgical procedure preferably utilizing the intercostal or subxyphoid space for valve introduction. In order to accomplish this, the valve is formed in such a manner that it can be compressed to fit within a delivery system and secondarily ejected from the delivery system into the annulus of a target valve such as a mitral valve or tricuspid valve.